Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Gunnar Lauge Nielsen a Department of Medicine, Odder Hospital,
DK-8300 Odder, Denmark, b Department of Clinical Epidemiology and
Medicine V, Aalborg and Aarhus University Hospitals, DK-8000 Aarhus C,
Denmark, c Danish Epidemiology Science Centre, Institute of Epidemiology
and Social Medicine, DK-8000 Aarhus C, d Department of Obstetrics and
Gynaecology and Medicine M, Aalborg Hospital, DK-9000 Aalborg, Denmark
Correspondence
to: G L Nielsen uxgln{at}aas.nja.dk
Objective:
To estimate the risk of adverse birth
outcome in women who take non-steroidal anti-inflammatory drugs during pregnancy.
Design and setting:
Population based cohort study
and a case-control study, both based on data from a prescription
registry, the Danish birth registry, and one county's hospital
discharge registry.
Participants:
Cohort study: 1462 pregnant women
who had taken up prescriptions for non-steroidal anti-inflammatory
drugs in the period from 30 days before conception to birth and 17 259 pregnant women who were not prescribed any drugs during pregnancy. Case-control study: 4268 women who had miscarriages, of whom 63 had
taken non-steroidal anti-inflammatory drugs, and 29 750 primiparous controls who had live births.
Main outcome measures:
Incidences of congenital
abnormality, low birth weight, preterm birth, and miscarriage.
Results:
Odds ratios for congenital abnormality,
low birth weight, and preterm birth among women who took up
prescriptions for non-steroidal anti-inflammatory drugs were 1.27 (95%
confidence interval 0.93 to 1.75), 0.79 (0.45 to 1.38), and 1.05 (0.80 to 1.39) respectively. Odds ratios for the taking up of prescriptions in the weeks before miscarriage ranged from 6.99 (2.75 to 17.74) when
prescriptions were taken up during the last week before the miscarriage
to 2.69 (1.81 to 4.00) when taken up between 7 and 9 weeks before. The
risk estimates were no different when the analysis was restricted to
missed abortions.
Conclusions:
Use of non-steroidal
anti-inflammatory drugs during pregnancy does not seem to increase the
risk of adverse birth outcome but is associated with increased risk of miscarriage.
Read all Rapid Responses